Physician profile
Thomas E Brinegar
NPI 1952329203
$587.69
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $370.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $132.36 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.52 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $97.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $84.71 | 2019-2020 | |
| Allergan, INC. | $72.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $40.89 | 2019-2020 | |
| Abbvie INC. | $17.08 | 2020 | |
| Pfizer INC. | $15.52 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.71 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.85 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Brinegar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.